Previous Close | 35.48 |
1-Year Change | 38.16% |
6-Months Change | 20.23% |
3-Months Change | 6.58% |
Moving Avg (50d) | 33.215 |
Moving Avg (200d) | 30.688 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.68B |
Beta (3-Years) | 0.96 |
Revenue Growth (ttm) | 14.58% |
Net Profit Margin (ttm) | -80.4% |
Return On Assets (ttm) | -50.93% |
EPS (ttm) | -8.66 |
PE Ratio (ttm) | -4.1 |
Dividend Yield | % |
Asset Description: | PTC Therapeutics, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Neutral |
Forecast Date: | 2024-09-05 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
36.19 | 37.254 | 37.964 | 39.028 | 40.802 | 42.576 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.